GRI Bio, Inc. SEC filings GRI
GRI Bio, Inc. has 402 filings in SEC EDGAR's recent list, going back to Sep 11, 2020. Its latest annual report, Form ARS, was filed on Sep 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Sep 28, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Jan 30, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Jul 11, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 14, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Aug 2, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 28, 2024 | Dec 31, 2023 |
| ARS | Annual report to shareholders | May 26, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Feb 24, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Feb 14, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Mar 29, 2021 | Dec 31, 2020 |
Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.